Cognition Therapeutics (CGTX) Cash from Investing Activities (2022 - 2024)
Cognition Therapeutics (CGTX) posted quarterly Cash from Investing Activities of -$1000.0 for Q4 2024, up 96.67% year-over-year from -$508.47 in Q1 2024, and up 96.67% quarter-over-quarter from -$30000.0 in Q4 2023.
Cognition Therapeutics (CGTX) Cash from Investing Activities (2022 - 2024) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Cash from Investing Activities for 3 consecutive years, with -$1000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Cash from Investing Activities rose 96.67% year-over-year to -$1000.0; the TTM figure through Dec 2024 stood at -$89000.0 (up 39.46% YoY), while the FY2025 annual figure was $9000.0, up 325.0% from the prior year.
- Cash from Investing Activities rose to -$1000.0 in Q4 2024 per CGTX's latest filing, from -$30000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$1000.0 in Q4 2024 and bottomed at -$134000.0 in Q1 2022.
- Historically, Cash from Investing Activities has averaged -$35444.4 across 3 years, with a median of -$23000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 350.0% — and 2024, when it jumped 96.67%.
- Cognition Therapeutics' Cash from Investing Activities stood at -$10000.0 in 2022, then slumped by 200.0% to -$30000.0 in 2023, then soared by 96.67% to -$1000.0 in 2024.
- Business Quant data shows CGTX's Cash from Investing Activities at -$1000.0 in Q4 2024, -$30000.0 in Q4 2023, and -$58000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -30,000.00 |
| Dec 31, 2023 | -30,000.00 |
| Sep 30, 2023 | -58,000.00 |
| Sep 30, 2023 | -58,000.00 |
| Jun 30, 2023 | -18,000.00 |
| Jun 30, 2023 | -18,000.00 |
| Mar 31, 2023 | -41,000.00 |
| Mar 31, 2023 | -41,000.00 |
| Dec 31, 2022 | -10,000.00 |
| Dec 31, 2022 | -10,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -134,000.00 |
| Mar 31, 2022 | -134,000.00 |